MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

@article{Treon2012MYD88LS,
  title={MYD88 L265P somatic mutation in Waldenstr{\"o}m's macroglobulinemia.},
  author={Steven P P Treon and Lian Xu and Guocai Yang and Yangsheng Zhou and Xia Liu and Yanglin Cao and Patricia Sheehy and Robert J. Manning and Christopher J. Patterson and Christina K. Tripsas and Luca Arcaini and Geraldine S. Pinkus and Scott J Rodig and Aliyah R. Sohani and Nancy Lee Harris and Jason M. Laramie and Donald A. Skifter and Stephen E. Lincoln and Zachary R. Hunter},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 9},
  pages={
          826-33
        }
}
BACKGROUND Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been delineated. METHODS We performed whole-genome sequencing of bone marrow LPL cells in 30 patients with Waldenström's macroglobulinemia, with paired normal-tissue and tumor-tissue sequencing in 10 patients. Sanger sequencing was used to validate the findings in samples from an expanded cohort of patients with LPL, those with other B… Expand
L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
TLDR
The results suggest that the L265P mutation is involved in the majority of Waldenström’s macroglobulinemia, and more frequently detected by BSiE1 digestion than by direct sequencing. Expand
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
TLDR
A whole exome-sequencing study of Waldenstrom macroglobulinemia confirmed a high frequency of MYD88 L265P mutation in WM, which may contribute to a better understanding of the physiopathogeny of WM. Expand
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
TLDR
A set of clinical assays to detect mutations in CXCR4 mutations in a clinical laboratory successfully validated and designed and validated Sanger sequencing and pyrosequencing assays and identified a novel missense variant and a previously reported variant of uncertain clinical significance. Expand
Choice of therapy for patients with Waldenstrom macroglobulinemia.
  • I. Ghobrial
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
Given the paucity of large clinical trials in WM, especially phase III clinical trials, the establishment of a standard treatment regimen that can be used as a benchmark for assessing novel, experimental agents is of critical importance. Expand
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
TLDR
Identification of MYD88 L265P mutation might be a new molecular‐based biomarker tool to add to the diagnostic and monitoring armamentarium for BNS. Expand
Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization
TLDR
The MYD88 L265P mutation appears to be frequently present in circulating cells in patients with WM, and MGUS, and these cells are amenable to immortalization by EBV. Expand
MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma
TLDR
Demonstration of the MYD88 L265 mutation is a valuable tool for the diagnosis of LPL, although some SMZL cases carrying the mutation do not fulfill the diagnostic criteria for LPL. Expand
MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
TLDR
The first report of high frequency MYD88 L265P mutations in Korean WM patients is reported, significantly associated with the presence of 6q deletions and associated with increased lymphocyte burden in BM biopsy. Expand
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
TLDR
Findings indicate that the allele-specific PCR developed is a useful diagnostic tool for patients with Waldenström's macroglobulinemia or IgM-MGUS, and may therefore also represent a useful prognostic marker. Expand
Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia
The genomic alterations that drive the signaling of Waldenstrom’s macroglobulinemia distinguish it from related malignancies such as marginal zone lymphoma, chronic lymphocytic leukemia, and IgMExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
How I treat Waldenström macroglobulinemia.
TLDR
The use of rituximab as monotherapy or in combination with cyclophosphamide, nucleoside analog, bortezomib, or thalidomide-based regimens can be considered for the first-line therapy of WM and should take into account specific treatment goals, future autologous stem cell transplantation eligibility, and long-term risks of secondary malignancies. Expand
Characterization of familial Waldenstrom's macroglobulinemia.
  • S. Treon, Z. Hunter, +12 authors C. Morton
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
Clinopathological data from 257 consecutive and unrelated Waldenström's macroglobulinemia patients suggest a high degree of clustering for B-cell disorders among first-degree relatives of patients with WM, along with distinct clinical features at presentation based on familial disease cluster patterns. Expand
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
TLDR
Encouraging data have led to the inclusion of bortezomib as a salvage treatment option in the recently updated Fourth International Workshop on Waldenström's Macroglobulinemia treatment recommendations. Expand
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.
TLDR
The findings of highly increased risks of developing LPL/WM, NHL, CLL, and MGUS support the operation of shared susceptibility genes that predispose to L PL/WM and other lymphoproliferative disorders. Expand
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.
TLDR
Despite similar outcomes of these 2 entities, SMZL appears as a disease with distinct clinical features and BM histology and a peculiar association with HCV infection. Expand
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second InternationalExpand
CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL).
TLDR
CD138 expression may constitute an additional aid in the distinction between WM and SMZL since both entities share overlapping clinical, immunophenotypic, and histopathologic characteristics. Expand
Oncogenically active MYD88 mutations in human lymphoma
TLDR
The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported. Expand
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
TLDR
The mutation spectrum for ARID1A differs between molecular subtypes of gastric cancer, and mutation prevalence is negatively associated with mutations in TP53, and alterations were associated with better prognosis in a stage-independent manner. Expand
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
TLDR
The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease. Expand
...
1
2
3
4
...